Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAM Strengthens Calls For Reforms To Stop Anticompetitive Tactics

Six Areas Listed Including Skinny Label Carve Outs

Executive Summary

The US Association for Accessible Medicines discussed six areas for reform during a recent US Senate Judiciary Committee hearing “shining a spotlight on the anti-competitive tactics used by some brand name pharmaceutical companies to delay patient access” to generics and biosimilars.

You may also be interested in...



Hikma Fails To Nix Vascepa Induced Infringement Case Early On

In a suit closely watched by industry, a US district magistrate judge found that Amarin had at least stated a plausible claim in its case accusing Hikma and US healthcare insurance provider Health Net of induced infringement of Vascepa method-of-use patents, which Hikma has carved out of its generic label.

FTC Urged To Investigate AbbVie’s IP Strategy On Humira

AbbVie delayed biosimilar competition to Humira “for far longer than warranted” and may have “engaged in other anti-competitive conduct to maintain its market share and pricing power” for the adalimumab brand, according to members of the US House of Representatives’ committee on oversight and reform. The US Federal Trade Commission has been urged to open a formal inquiry into the originator’s conduct.

AAM Opposes Oregon’s SB 764 Settlements Bill

Proposed state legislation restricting patent settlements set out in Oregon’s SB 764 bill is “unnecessary,” the AAM has insisted, opposing the “unconstitutional” legislation by citing delayed patient access to affordable medicines, the obstruction of expedited patent settlements and benefits to brand-name pharmaceutical companies which will eventually lead to price rises. 

Related Content

Topics

UsernamePublicRestriction

Register

GB151091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel